GSK-200911

Study Sponsor: GSK

Study Title

A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicistat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-naive adults

Medicine or Vaccine (generic name)

GSK2838232

Sponsor Identification Number

200911

Trial Registry Identification Number(#'s)

NCT03045861

Medical Condition

Infection, Human Immunodeficiency Virus

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=200911

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT03045861

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.

Date Added to this Site

January 2020